Current Value
$0.391 Year Return
Current Value
$0.391 Year Return
Yahoo
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"
Yahoo
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology. UNIONDALE, NY, June 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the successful completion of a key validation study eva
Yahoo
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for
Yahoo
ProPhase Labs Inc (PRPH) outlines cost reductions, promising cancer test developments, and strategic alternatives amidst financial hurdles and NASDAQ compliance issues.
SeekingAlpha
ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ETCompany ParticipantsNoella Alexander-Young - Virtual Event...
Yahoo
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics a
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EDIT | 35.50% | $188.35M | -50.44% | 0.00% |
| ADEA | 34.98% | $1.54B | +26.95% | 1.41% |
| PSEC | 34.48% | - | - | 18.43% |
| DVN | 33.53% | $20.96B | -31.65% | 3.47% |
| VMI | 33.02% | $6.73B | +24.90% | 0.77% |
| WFRD | 32.98% | $3.78B | -58.13% | 1.90% |
| VTS | 32.79% | $871.90M | -7.15% | 9.59% |
| EC | 32.69% | $18.30B | -20.11% | 0.00% |
| NXST | 32.63% | $5.36B | +6.78% | 3.99% |
| KRP | 32.58% | $1.30B | -15.91% | 12.13% |
| HAL | 32.22% | $18.23B | -36.91% | 3.19% |
| LBRT | 31.98% | $1.93B | -41.12% | 2.57% |
| SD | 31.89% | $397.32M | -15.72% | 4.02% |
| BSM | 31.82% | $2.78B | -17.10% | 11.39% |
| CIVI | 31.78% | $2.73B | -56.92% | 6.77% |
| OBDC | 31.77% | $7.35B | -6.59% | 10.26% |
| BRY | 31.43% | $225.80M | -55.37% | 8.84% |
| CHRD | 31.41% | $5.82B | -40.99% | 6.45% |
| FANG | 30.89% | $40.96B | -31.58% | 3.70% |
| USAC | 30.85% | $2.87B | +2.95% | 8.60% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| TARS | -0.03% | $1.68B | +45.15% | 0.00% |
| INSG | 0.04% | $132.52M | -23.94% | 0.00% |
| ADMA | 0.07% | $4.27B | +56.84% | 0.00% |
| LRN | -0.08% | $6.16B | +105.86% | 0.00% |
| IMDX | -0.10% | $86.94M | +2.70% | 0.00% |
| COST | -0.11% | $437.25B | +14.73% | 0.49% |
| MSIF | -0.14% | $756.27M | +33.83% | 7.70% |
| WNC | -0.17% | $463.08M | -49.17% | 2.84% |
| CRVL | -0.21% | $5.37B | +21.01% | 0.00% |
| WWW | -0.23% | $1.55B | +45.76% | 2.62% |
| HALO | 0.25% | $6.52B | +3.16% | 0.00% |
| UEIC | -0.25% | $88.11M | -40.00% | 0.00% |
| PSN | 0.25% | $7.77B | -9.01% | 0.00% |
| KROS | -0.26% | $541.81M | -68.84% | 0.00% |
| MRCY | 0.27% | $3.03B | +74.95% | 0.00% |
| AMSF | 0.28% | $832.88M | +5.01% | 3.52% |
| BULL | -0.29% | $5.80B | +12.65% | 0.00% |
| ALRM | 0.29% | $2.84B | -9.59% | 0.00% |
| AVNS | 0.30% | $578.97M | -35.79% | 0.00% |
| DVA | 0.31% | $11.08B | +5.97% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PXJ | 34.55% | $25.32M | 0.66% |
| RSPG | 33.98% | $430.78M | 0.4% |
| IGE | 33.96% | $604.05M | 0.41% |
| FXN | 33.65% | $277.29M | 0.62% |
| GNR | 33.34% | $2.81B | 0.4% |
| PFEB | 33.30% | $887.85M | 0.79% |
| UJAN | 33.14% | $261.30M | 0.79% |
| IYE | 32.72% | $1.17B | 0.39% |
| FCG | 32.64% | $339.13M | 0.57% |
| FTXN | 32.48% | $122.01M | 0.6% |
| MLPX | 32.48% | $2.65B | 0.45% |
| XLE | 32.28% | $26.99B | 0.09% |
| FENY | 32.23% | $1.27B | 0.084% |
| XOP | 32.21% | $1.90B | 0.35% |
| XES | 32.19% | $144.30M | 0.35% |
| IEO | 32.04% | $495.71M | 0.4% |
| VDE | 32.03% | $7.14B | 0.09% |
| SPGP | 31.68% | $2.79B | 0.36% |
| PJAN | 31.64% | $1.29B | 0.79% |
| BJAN | 31.47% | $310.31M | 0.79% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VSA | -26.15% | $8.76M | -18.25% | 0.00% |
| TASK | -17.15% | $1.49B | +25.32% | 0.00% |
| NHTC | -14.43% | $51.35M | -35.08% | 17.78% |
| BLKB | -13.44% | $3.19B | -13.07% | 0.00% |
| AXON | -12.22% | $60.36B | +164.47% | 0.00% |
| STG | -11.04% | $30.47M | -21.87% | 0.00% |
| KR | -10.95% | $47.17B | +41.48% | 1.81% |
| BJ | -10.22% | $14.13B | +25.00% | 0.00% |
| MKTX | -9.16% | $8.37B | +15.12% | 1.35% |
| CYCN | -8.94% | $9.95M | +33.33% | 0.00% |
| FRD | -8.54% | $116.23M | +14.18% | 0.97% |
| UNH | -8.52% | $295.85B | -34.54% | 2.69% |
| DXYZ | -7.92% | - | - | 0.00% |
| AWK | -7.72% | $27.80B | +10.98% | 2.21% |
| MSEX | -7.67% | $1.01B | +5.19% | 2.41% |
| ED | -7.29% | $36.31B | +13.27% | 3.35% |
| CPSH | -7.18% | $39.66M | +61.54% | 0.00% |
| FARO | -6.91% | $848.40M | +175.36% | 0.00% |
| FTS | -6.90% | $23.99B | +23.37% | 3.67% |
| LITB | -6.88% | $22.07M | -77.41% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| NFLT | -0.11% | $269.20M | 0.5% |
| LQDW | 0.11% | $250.78M | 0.34% |
| IBMO | -0.34% | $526.03M | 0.18% |
| KCCA | -0.39% | $105.90M | 0.87% |
| KRBN | 0.45% | $162.64M | 0.85% |
| PWZ | -0.73% | $748.91M | 0.28% |
| FXB | -0.77% | $92.39M | 0.4% |
| PTBD | -0.86% | $138.06M | 0.6% |
| FMF | -0.96% | $157.12M | 0.95% |
| VRIG | 1.04% | $1.20B | 0.3% |
| JPIE | 1.35% | $4.00B | 0.39% |
| DRSK | -1.52% | $1.27B | 0.78% |
| USDU | 1.54% | $163.19M | 0.5% |
| YEAR | 1.56% | $1.47B | 0.25% |
| USFR | 1.59% | $18.59B | 0.15% |
| IBMP | -1.60% | $553.36M | 0.18% |
| BAR | 1.67% | $1.10B | 0.1749% |
| VNLA | 1.80% | $2.62B | 0.23% |
| BGRN | -1.84% | $402.97M | 0.2% |
| CANE | 1.85% | $10.58M | 0.29% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -32.25% | $99.49M | 0.59% |
| VIXY | -25.27% | $165.58M | 0.85% |
| BTAL | -21.79% | $295.67M | 1.43% |
| SPTS | -21.60% | $5.77B | 0.03% |
| SHYM | -20.69% | $354.58M | 0.35% |
| IVOL | -18.91% | $348.25M | 1.02% |
| VGSH | -18.62% | $22.77B | 0.03% |
| XONE | -18.59% | $585.85M | 0.03% |
| UTWO | -18.45% | $379.27M | 0.15% |
| IBTI | -18.08% | $1.06B | 0.07% |
| IBTJ | -18.05% | $684.86M | 0.07% |
| GSST | -17.98% | $919.83M | 0.16% |
| GBIL | -17.70% | $6.37B | 0.12% |
| AGZ | -17.37% | $613.46M | 0.2% |
| IEI | -17.12% | $15.41B | 0.15% |
| FMHI | -17.11% | $753.22M | 0.7% |
| SPTI | -17.08% | $8.80B | 0.03% |
| VGIT | -16.90% | $31.79B | 0.04% |
| MLN | -16.78% | $540.39M | 0.24% |
| DFNM | -16.77% | $1.57B | 0.17% |
